Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 70Neoplasms 13Neoplasm Metastasis 7Brain Neoplasms 7Head and Neck Neoplasms 6Breast Neoplasms, Male 6Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Ovarian Neoplasms 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Salivary Gland Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Osteitis Deformans 2Neuroma, Acoustic 2Neurofibromatosis 2 2Inflammatory Breast Neoplasms 2Glioblastoma 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Ependymoma 2Colorectal Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Hepatocellular 2Bile Duct Neoplasms 2

Interventions

Gemcitabine 153Fluorouracil 45Capecitabine 45130-nm albumin-bound paclitaxel 43Oxaliplatin 42Albumin-Bound Paclitaxel 39Leucovorin 31Erlotinib Hydrochloride 30pembrolizumab 23Radiotherapy 22Irinotecan 22Radiosurgery 20Bevacizumab 19Docetaxel 17Cyclophosphamide 17Taxes 13Cisplatin 13Cetuximab 13folfirinox 12Nivolumab 11Surgical Procedures, Operative 7Paclitaxel 7Ipilimumab 7dehydroftorafur 6Standard of Care 6Radiation 6Magnetic Resonance Spectroscopy 6spartalizumab 5ruxolitinib 5durvalumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Pancreatic Neoplasms × Lapatinib × Clear all
NCT00881621 2025-03-03

Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer

Georgetown University

Phase 2 Terminated
17 enrolled 10 charts
Gastrointestinal

Pancreatic Neoplasms

NCT00447122 2022-03-08

BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer

Brown University

Phase 1 Terminated
25 enrolled 9 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡